Effectiveness of benzodiazepine receptor agonists in the treatment of insomnia: An examination of response and remission rates

Sleep

Volumn 40, Issue 2, 2017, Pages

  Pillai, Vivek ^a   Roth, Thomas ^a   Roehrs, Timothy ^a   Moss, Kenneth ^a   Peterson, Edward L ^a   Drake, Christopher L ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Benzodiazepine receptor agonists; Comorbidity; Insomnia; Minimally important difference; Remission

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT;

ADULT; AGED; CHRONIC DISEASE; DOSE RESPONSE; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME;

ADULT; AGED; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GABA-A RECEPTOR AGONISTS; HUMANS; INDUCTION CHEMOTHERAPY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME;

EID: 85030615231     PISSN: 01618105     EISSN: 15509109     Source Type: Journal    
DOI: 10.1093/sleep/zsw044     Document Type: Article

References (66)

1. Ebert B, Wafford KA, Deacon S. Treating insomnia: Current and investigational pharmacological approaches. Pharmacol Ther. 2006; 112(3): 612–629.
2. Walsh JK, Roth T. Pharmacologic treatment of insomnia benzodiazepine receptor agonists. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine (Sixth Edition). Vol 6. 6th ed. St. Louis, MO: Elsevier; 2016: 832–841.
3. Krystal AD. A compendium of placebo-controlled trials of the risks/ benefits of pharmacological treatments for insomnia: the empirical basis for U.S. clinical practice. Sleep Med Rev. 2009; 13(4): 265–274.
4. Davidson JR, Aime A, Ivers H, Morin CM. Characteristics of individuals with insomnia who seek treatment in a clinical setting versus those who volunteer for a randomized controlled trial. Behav Sleep Med. 2009; 7(1): 37–52.
5. Stepanski E, Koshorek G, Zorick F, Glinn M, Roehrs T, Roth T. Characteristics of individuals who do or do not seek treatment for chronic insomnia. Psychosomatics. 1989; 30(4): 421–427.
6. Krakow B, Ulibarri VA, Romero EA. Patients with treatment-resistant insomnia taking nightly prescription medications for sleep: a retrospective assessment of diagnostic and treatment variables. Prim Care Companion J Clin Psychiatry. 2010; 12(4): 1–12. doi:10.4088/ PCC.09m00873bro.
7. American Psychiatrc Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5TM (5th Ed.). Arlington, VA: American Psychiatric Publishing, Inc.; 2013. http://search.ebscohost.com/login.aspx?direct = true&db = psyh&AN = 2013-14907-000&site = ehost-live Accessed April 1, 2016.
8. Bonnet MH, Arand DL. 24-Hour metabolic rate in insomniacs and matched normal sleepers. Sleep. 1995; 18(7): 581–588. http://www.ncbi.nlm.nih.gov/pubmed/8552929 Accessed October 31, 2015.
9. Vgontzas AN, Bixler EO, Lin HM, et al. Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: clinical implications. J Clin Endocrinol Metab. 2001; 86(8): 3787–3794.
10. Roehrs TA, Randall S, Harris E, Maan R, Roth T. MSLT in primary insomnia: stability and relation to nocturnal sleep. Sleep. 2011; 34(12): 1647–1652.
11. Randall S, Roehrs TA, Roth T. Efficacy of eight months of nightly zolpidem: a prospective placebo-controlled study. Sleep. 2012; 35(11): 1551–1557.
12. Walsh JK, Krystal AD, Amato DA, et al. Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. Sleep. 2007; 30(8): 959–968. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid = 1978384&tool = pmcentrez&rendertype = abstract Accessed April 20, 2016.
13. Scharf MB, Black J, Hull S, Landin R, Farber R. Long-term nightly treatment with indiplon in adults with primary insomnia: results of a double-blind, placebo-controlled, 3-month study. Sleep. 2007; 30(6): 743–752. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid = 1978349&tool = pmcentrez&rendertype = abstract Accessed April 27, 2016.
14. Katz DA, McHorney CA. Clinical correlates of insomnia in patients with chronic illness. Arch Intern Med. 1998; 158(10):1099–1107. http://www.ncbi.nlm.nih.gov/pubmed/9605781 Accessed April 27, 2016.
15. Lichstein K, Taylor DJ, McCrae CS, Ruiter ME. Insomnia: epidemiology and risk factors. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine (Fifth Edition). Philadelphia, PA: W.B. Saunders; 2011: 827–837. doi:http://dx.doi.org/10.1016/B978-1-4160-6645-3.00071-2.
16. Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev. 2002; 6(2): 97–111.
17. U.S. Food and Drug Administration. Lunesta (eszopiclone) Tablets: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER). 2008. http://www.fda.gov.proxy.lib.umich.edu/Safety/MedWatch/SafetyInformation/Safety-RelatedDrugLabelingChanges/ucm106688.htm Accessed April 1, 2016.
18. U.S. Food and Drug Administration. AMBIEN: Highlights of Prescribing Information. 2004. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019908s035,021774s016lbl.pdf Accessed April 1, 2016.
19. Fava M, McCall WV, Krystal A, et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry. 2006; 59(11): 1052–1060.
20. Fava M, Asnis GM, Shrivastava RK, et al. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial. J Clin Psychiatry. 2011; 72(7): 914–928.
21. Asnis GM, Chakraburtty A, DuBoff EA, et al. Zolpidem for persistent insomnia in SSRI-treated depressed patients. J Clin Psychiatry. 1999; 60(10): 668–676. http://www.ncbi.nlm.nih.gov/pubmed/10549683 Accessed April 27, 2016.
22. Pollack M, Kinrys G, Krystal A, et al. Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. Arch Gen Psychiatry. 2008; 65(5): 551–562.
23. Pollack MH, Hoge EA, Worthington JJ, et al. Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011; 72(7): 892–897.
24. Fava M, Asnis GM, Shrivastava R, et al. Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder. J Clin Psychopharmacol. 2009; 29(3): 222–230.
25. Walsh JK, Muehlbach MJ, Lauter SA, Hilliker NA, Schweitzer PK. Effects of triazolam on sleep, daytime sleepiness, and morning stiffness in patients with rheumatoid arthritis. J Rheumatol. 1996; 23(2): 245–252. http://www.ncbi.nlm.nih.gov/pubmed/8882027 Accessed April 24, 2016.
26. Roth T, Price JM, Amato DA, Rubens RP, Roach JM, Schnitzer TJ. The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study. Prim Care Companion J Clin Psychiatry. 2009; 11(6): 292–301.
27. Soares CN, Joffe H, Rubens R, Caron J, Roth T, Cohen L. Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial. Obstet Gynecol. 2006; 108(6): 1402–1410.
28. Joffe H, Petrillo L, Viguera A, et al. Eszopiclone improves insomnia and depressive and anxious symptoms in perimenopausal and postmenopausal women with hot flashes: a randomized, double-blinded, placebo-controlled crossover trial. Am J Obstet Gynecol. 2010; 202(2): 171.e1–171.e11.
29. Goforth HW, Preud’homme XA, Krystal AD. A randomized, double-blind, placebo-controlled trial of eszopiclone for the treatment of insomnia in patients with chronic low back pain. Sleep. 2014; 37(6): 1053–1060.
30. Bertisch SM, Herzig SJ, Winkelman JW, Buettner C. National use of prescription medications for insomnia: NHANES 1999–2010. Sleep. 2014; 37(2): 343–349. doi:10.5665/sleep.3410.
31. Balkrishnan R, Rasu RS, Rajagopalan R. Physician and patient determinants of pharmacologic treatment of sleep difficulties in outpatient settings in the United States. Sleep. 2005; 28(6): 715–719. http://www.ncbi.nlm.nih.gov/pubmed/16477958 Accessed April 28, 2016.
32. Moloney ME, Konrad TR, Zimmer CR. The medicalization of sleeplessness: a public health concern. Am J Public Health. 2011; 101(8): 1429–1433.
33. Walsh JK. Drugs used to treat insomnia in 2002: regulatory-based rather than evidence-based medicine. Sleep. 2004; 27(8): 1441–1442. http://www.ncbi.nlm.nih.gov/pubmed/15683131 Accessed April 28, 2016.
34. Barbone F, McMahon AD, Davey PG, et al. Association of road-traffic accidents with benzodiazepine use. Lancet (London, England). 1998; 352(9137): 1331–1336. http://www.ncbi.nlm.nih.gov/pubmed/9802269 Accessed April 28, 2016.
35. Billioti de Gage S, Bégaud B, Bazin F, et al. Benzodiazepine use and risk of dementia: prospective population based study. BMJ. 2012; 345: e6231. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid = 3460255&tool = pmcentrez&rendertype = abstract Accessed April 28, 2016.
36. Moore N, Pariente A, Bégaud B. Why are benzodiazepines not yet controlled substances? JAMA Psychiatry. 2015; 72(2): 110–111.
37. Ohayon MM, Caulet M, Arbus L, et al. Are prescribed medications effective in the treatment of insomnia complaints? J Psychosom Res. 1999; 47(4): 359–368. http://www.ncbi.nlm.nih.gov/pubmed/10616230 Accessed April 24, 2016.
38. Balter MB, Uhlenhuth EH. The beneficial and adverse effects of hypnotics. J Clin Psychiatry. 1991; 52(Suppl): 16–23. http://www.ncbi.nlm.nih.gov/pubmed/2071567 Accessed April 24, 2016.
39. Yang M, Morin CM, Schaefer K, Wallenstein GV. Interpreting score differences in the Insomnia Severity Index: using health-related outcomes to define the minimally important difference. Curr Med Res Opin. 2009; 25(10): 2487–2494.
40. Morin CM, Belleville G, Bélanger L, Ivers H. The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep. 2011; 34(5): 601–608.
41. Bastien CH, Vallières A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med. 2001; 2(4): 297–307. http://www.ncbi.nlm.nih.gov/pubmed/11438246 Accessed February 24, 2016.
42. IBM SPSS Statistics for Windows, Version 23.0. 2015.
43. Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol. 1989; 129(1): 125–137.
44. Roth T, Coulouvrat C, Hajak G, et al. Prevalence and perceived health associated with insomnia based on DSM-IV-TR; International Statistical Classification of Diseases and Related Health Problems, Tenth Revision; and Research Diagnostic Criteria/International Classification of Sleep Disorders. Biol Psychiatry. 2011; 69(6): 592–600. doi:10.1016/j. biopsych.2010.10.023.
45. Lichstein KL, Durrence HH, Taylor DJ, Bush AJ, Riedel BW. Quantitative criteria for insomnia. Behav Res Ther. 2003; 41(4): 427–445. http://www.ncbi.nlm.nih.gov/pubmed/12643966 Accessed October 31, 2015.
46. Moul DE, Hall M, Pilkonis PA, Buysse DJ. Self-report measures of insomnia in adults: rationales, choices, and needs. Sleep Med Rev. 2004; 8(3): 177–198.
47. Drake CL, Vargas I, Roth T, Friedman NP. Quantitative measures of nocturnal insomnia symptoms predict greater deficits across multiple daytime impairment domains. Behav Sleep Med. 2015; 13(1): 73–87.
48. NIH State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults. J Clin Sleep Med. 2005; 1(4): 412–421. http://www.ncbi.nlm.nih.gov/pubmed/17564412 Accessed October 11, 2015.
49. Krystal AD, McCall WV, Fava M, et al. Eszopiclone treatment for insomnia: effect size comparisons in patients with primary insomnia and insomnia with medical and psychiatric comorbidity. Prim care companion CNS Disord. 2012; 14(4): 1–31. doi:10.4088/PCC.11m01296.
50. Michelson D, Snyder E, Paradis E, et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014; 13(5): 461–471.
51. Herring WJ, Connor KM, Ivgy-May N, et al. Suvorexant in patients with i: results from two 3-month randomized controlled clinical trials. Biol Psychiatry. 2016; 79(2): 136–148.
52. Krystal AD, Lankford A, Durrence HH, et al. Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. Sleep. 2011; 34(10): 1433–1442.
53. Schutte-Rodin S, Broch L, Buysse D, Dorsey C, Sateia M. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med. 2008; 4(5): 487–504. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid = 2576317&tool = pmcentrez&rendertype = abstract Accessed April 12, 2016.
54. Krystal AD. Pharmacologic treatment of insomnia: other medications. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine (Sixth Edition). 6th ed. St. Louis, MO: Elsevier; 2016: 842–854.
55. Trauer JM, Qian MY, Doyle JS, Rajaratnam SM, Cunnington D. Cognitive behavioral therapy for chronic insomnia: a systematic review and meta-analysis. Ann Intern Med. 2015; 163(3): 191–204.
56. Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016; 165: 125–133. doi:10.7326/M15-2175.
57. Ancoli-Israel S, Roth T. Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. I. Sleep. 1999; 22(Suppl 2): S347–S353.
58. O’Keefe DJ. Colloquy: should familywise alpha be adjusted?: against familywise alpha adjustment. Hum Commun Res. 2003; 29(3): 431–447. doi:10.1093/hcr/29.3.431.
59. Kaufmann CN, Spira AP, Alexander GC, Rutkow L, Mojtabai R. Trends in prescribing of sedative-hypnotic medications in the USA: 1993–2010. Pharmacoepidemiol Drug Saf. 2016; 25: 637–645. doi:10.1002/ pds.3951.
60. McClintock SM, Husain MM, Wisniewski SR, et al. Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. J Clin Psychopharmacol. 2011; 31(2): 180–186.
61. Baglioni C, Battagliese G, Feige B, et al. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. J Affect Disord. 2011; 135(1–3): 10–19.
62. Li Y, Vgontzas AN, Fernandez-Mendoza J, et al. Insomnia with physiological hyperarousal is associated with hypertension. Hypertension. 2015; 65(3): 644–650.
63. Sivertsen B, Lallukka T, Salo P, et al. Insomnia as a risk factor for ill health: results from the large population-based prospective HUNT Study in Norway. J Sleep Res. 2014; 23(2): 124–132.
64. Canivet C, Nilsson PM, Lindeberg SI, Karasek R, Östergren PO. Insomnia increases risk for cardiovascular events in women and in men with low socioeconomic status: a longitudinal, register-based study. J Psychosom Res. 2014; 76(4): 292–299.
65. Freeman D, Sheaves B, Goodwin GM, et al. Effects of cognitive behavioural therapy for insomnia on the mental health of university students: study protocol for a randomized controlled trial. Trials. 2015; 16: 236.
66. Gosling JA, Glozier N, Griffiths K, et al. The GoodNight study–online CBT for insomnia for the indicated prevention of depression: study protocol for a randomised controlled trial. Trials. 2014; 15: 56.